Oncology

By combining vast datasets with patient-driven advocacy, a new alliance offers hope for angiosarcoma patients and a new model for rare disease research.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

IBA's deal to build Brazil's first proton therapy center is more than a medical breakthrough; it's a high-stakes play for market dominance in Latin America.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

A new partnership aims to leverage corporate science and community trust to reverse declining cancer screenings. But can this model truly bridge the gap?

Calidi Biotherapeutics' RedTail platform uses a virus to make tumors produce their own medicine, a strategy that could finally defeat solid cancers.

As McKesson prepares its August 5th earnings, all eyes are on its strategic overhaul. Will bold moves in oncology and tech deliver on profit promises?

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Following a $30M funding round, Mammogen appoints Dr. Elise Berman as CMO to spearhead its genTRU-breast™ test, aiming to solve the dense breast dilemma.

A new $5M partnership promises better patient support. We analyze the model, the money, and the ethical tightrope of pharma-nonprofit collaborations.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

A pivotal NCCN guideline update for bladder cancer validates Natera's Signatera test, ushering in a new era of personalized, MRD-guided cancer treatment.

A new report reveals high patient volume is the top cause of burnout in oncology. Now, centers are betting on AI and optimization, not just hiring, to survive.

Spotlight Medical's myStage Dx secures tough IVDR CE mark, using AI on standard lab slides to help doctors pinpoint which patients can safely avoid chemo.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.